Amerise Biosciences has notified the BSE regarding the book closure period for its Annual General Meeting (AGM). The company’s register of members and share transfer books will remain closed from September 17, 2026 to September 24, 2026.

This closure is necessary to determine the record of members eligible for the AGM scheduled for September 24, 2026. The intimation was issued pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

E-Voting Schedule

Shareholders eligible to vote must hold equity shares as of the cut-off date. The e-voting process is structured as follows:

• Commencement: Monday, September 21, 2026 at 9:00 am
• Conclusion: Wednesday, September 23, 2026 at 5:00 pm
• Cut-off Date: Wednesday, September 17, 2026

The cut-off date determines eligibility for voting either electronically or in person at the AGM. Albert Hines, Director, signed the communication addressed to the Department of Corporate Services at BSE Limited.

Amerise Biosciences reported a net loss of ₹8.14 lakh for the quarter ended June 30, 2026 (Q1FY27), a significant deterioration from the net profit of ₹6.13 lakh recorded in the preceding quarter. The financial setback was primarily driven by the absence of revenue from product sales and a substantial rise in other operating expenses, which jumped to ₹7.21 lakh from ₹0.34 lakh in Q4FY26. Total income for the quarter stood at nil, as both gross revenue from sale of products and other operating revenue were zero, compared to ₹7.92 lakh in the previous quarter.

The Board of Directors approved the unaudited standalone financial results on August 03, 2026, pursuant to Regulation 33 read with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The meeting commenced at 04:50 PM and concluded at 05:10 PM at the company’s registered office in Ahmedabad. The results have been reviewed by the Audit Committee and subjected to a limited review by the statutory auditors, Bipin & Co., Chartered Accountants.

Financial Performance Breakdown

The company’s total expenses for Q1FY27 amounted to ₹8.14 lakh, comprising employee benefit expenses of ₹0.94 lakh and other expenses of ₹7.21 lakh. In contrast, total expenses in the previous quarter were significantly lower at ₹1.79 lakh. The surge in other expenses outpaced the reduction in employee benefits, which fell to ₹0.94 lakh from ₹1.45 lakh in Q4FY26. No finance costs or depreciation expenses were recorded during the period.

Year-to-date figures for FY26 showed a net profit of ₹1.61 lakh on total income of ₹25.52 lakh. For the comparative quarter ended June 30, 2025 (Q1FY26), the company had reported a net loss of ₹0.81 lakh on total income of ₹6.37 lakh. The current quarter’s performance marks a deeper loss than the same period last year, indicating ongoing operational challenges.

What the Numbers Show

The most critical aspect of Amerise Biosciences’ Q1FY27 results is the complete cessation of revenue generation. With both gross revenue and other operating revenue at nil, the company incurred costs without any offsetting inflows. The spike in 'other expenses' to ₹7.21 lakh suggests potential one-time charges or increased administrative overheads that were not present in the prior quarter. This divergence between zero revenue and rising non-employee expenses highlights a period of operational dormancy or transition, where fixed costs continue to accrue while business activity remains stalled. The paid-up equity share capital remained unchanged at ₹660.69 lakh.